Better access through better evidence
We turn fragmented data into insight that decision-makers trust. That cuts uncertainty, speeds up approvals and makes access more predictable in resource-constrained systems.
0% · Initialising analytics engine
Health Economics · HTA · Market Access · GCC & MENA
We turn fragmented health data into evidence that payers and HTA bodies can act on. The result is less uncertainty, faster approvals and more predictable access to high-value therapies.
Our conviction
Health systems don’t lack data. They lack evidence they can act on. We turn fragmented data into insight that decisions can rest on, grounded in local reality, so the right therapies reach the right patients.
About QALYt
We turn fragmented data into insight that decision-makers trust. That cuts uncertainty, speeds up approvals and makes access more predictable in resource-constrained systems.
HTA, HEOR, real-world evidence, analytics, pricing and managed-entry solutions, aligned with national guidelines and regional payer expectations.
We partner with pharma companies and public-health institutions, from readiness assessment through to capability building and policy execution.
“QALYt” echoes the Quality-Adjusted Life Year: measurable patient value at the centre of every access decision.
Our services
Predictive modelling, forecasting and validation for pre- and post-market decisions, plus epidemiology, burden-of-disease and public-health intervention evaluation.
Cost-effectiveness, budget impact, QALY modelling, indirect comparisons, Markov, decision-tree and microsimulation models, MCDA and uncertainty analysis.
HTA dossiers and localisation, pricing and reimbursement strategy, and value communication, along with managed-entry design, policy intelligence and stakeholder advisory.
Systematic and rapid reviews and meta-analyses, turning clinical evidence into HTA- and payer-aligned positioning and white papers.
How we work with you
Map current evidence, find gaps against local HTA and payer requirements, and analyse policy, pricing and reimbursement in target markets.
HEOR, models, RWE and reviews, designed around local data and national guidelines.
Localised dossiers, pricing and managed-entry strategies, and value communication that payers can act on.
Stakeholder engagement and capacity building so access outcomes last beyond the project.
12 capability areas
Select a card to see the market gap and the value of closing it.
Where we deliver
Why regional, not global? Global evidence often falls short locally. Every model and dossier we build is grounded in local data, national guidelines and regional payer expectations.
FAQs
QALYt is a health economics, HTA and market access consultancy for MENA and the GCC. We turn fragmented data into HTA dossiers, economic models, real-world evidence and pricing strategies.
The name comes from the Quality-Adjusted Life Year, which puts measurable patient value at the centre of every access decision.
Pharmaceutical companies seeking market access, reimbursement and evidence strategy; and government health entities building HTA capacity and policy.
Core delivery across Saudi Arabia, the UAE (including Dubai), Qatar, Kuwait, Bahrain, Oman and Iraq, extending across the wider MENA region.
Global evidence often falls short in local contexts. Our work is grounded in local data, national guidelines and regional payer expectations.
Have a project?
Clarify any uncertainties and get a smooth, hassle-free start. Send a brief or request a quote.
Answers are generated by AI and may contain errors. Please do not share confidential information.